Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 737-743

  Pahuja, Meera ^a,b   Grobler, Anneke ^b   Glesby, Marshall J ^a   Karim, Farina ^b   Parker, Gary ^b   Gumede, Sizwe ^b   Naidoo, Kogieleum ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SOUTH AFRICA; STAVUDINE; YOUNG ADULT;

EID: 84861712524     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2087     Document Type: Article

References (19)

1. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374:921-933.
2. Republic of South Africa. Country progress report on the declaration of commitment on HIV/AIDS: 2010 report. pp 15. (Updated 31 March 2010. Accessed 10 May 2010.) Available from http://data.unaids.org/pub/Report/2010/southafrica- 2010-country-progress-report-en.pdf
3. National Department of Health, South Africa. National HIV and syphilis prevalence survey South Africa 2010. (Accessed 13 February 2012.) Available from www.doh.gov.za/docs/reports/2011/hiv-aids-survey.pdf
4. Renaud-Théry F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 2007; 21 Suppl 4:S89-S95. (Pubitemid 47051754)
5. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resourcepoor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-470. (Pubitemid 40712431)
6. Simpson DM, Tagliati M. Nucleoside analog-associated peripheral neuropathy in human-immunodeficiency-virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:153-161.
7. Sánchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6:197-202. (Pubitemid 41601131)
8. McComsey GA, Lo Re V, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIVinfected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46:1290-1296. (Pubitemid 351589916)
9. World Health Organization. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents. (Updated 4 May 2007. Accessed 15 June 2010.) Available from http://www.who.int/hiv/art/ ARTadultsaddendum.pdf
10. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. (Updated 30 November 2009. Accessed 13 February 2012.) Available from http://www.who.int/hiv/pub/arv/rapid-advice-art. pdf
11. Treatment action campaign. Detailed commentary on updated ART guidelines. (Updated 23 April 2010. Accessed 13 February 2012.) Available from http://tac.org.za/community/node/2854
12. Division of AIDS table for grading the severity of adult and pediatric adverse events. (Updated 28 December 2004. Accessed 12 May 2010.) Available from http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS-AE-GradingTable- FinalDec2004.pdf
13. Wadley AL, Cherry CL, Price P, et al. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage 2011; 41:700-706.
14. Maritz J, Benatar M, Dave JA, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 2010; 41:599-606.
15. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy - a randomized controlled trial. JAMA 1998; 280:1590-1595. (Pubitemid 28520647)
16. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010; 11:121-129.
17. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res 2010; 86:227-229.
18. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41:53-58. (Pubitemid 41786019)
19. Van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte E, Reid T. Stavudine-and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010; 104:148-153.